TERNS PHARMACEUTICALS INC's ticker is TERN and the CUSIP is 880881107. A total of 45 filers reported holding TERNS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $107,577 | -40.4% | 21,387 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $180,486 | +802.4% | 20,627 | +202.8% | 0.00% | – |
| Q1 2022 | $20,000 | -61.5% | 6,811 | -6.6% | 0.00% | – |
| Q4 2021 | $52,000 | -33.3% | 7,289 | -2.9% | 0.00% | – |
| Q3 2021 | $78,000 | +30.0% | 7,507 | +53.7% | 0.00% | – |
| Q2 2021 | $60,000 | -46.4% | 4,883 | -3.8% | 0.00% | – |
| Q1 2021 | $112,000 | – | 5,075 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 970,000 | $8,487,500 | 5.75% |
| VR Adviser, LLC | 2,972,869 | $26,012,604 | 4.16% |
| Vivo Capital, LLC | 6,657,992 | $58,257,430 | 4.02% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,561,835 | $48,666,056 | 2.60% |
| Fairmount Funds Management LLC | 2,040,000 | $17,850,000 | 2.52% |
| Decheng Capital Management III (Cayman), LLC | 714,285 | $6,249,994 | 1.96% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 599,668 | $5,247,095 | 1.62% |
| Orbimed Advisors | 7,619,135 | $66,667,431 | 1.21% |
| CROSSPOINT FINANCIAL, LLC | 12,054 | $105,473 | 1.07% |
| HighVista Strategies LLC | 179,670 | $1,572,113 | 0.72% |